Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2005 1
2006 1
2007 1
2008 1
2009 1
2010 2
2011 5
2012 2
2013 4
2014 7
2015 4
2016 1
2017 4
2018 3
2019 6
2020 5
2021 3
2022 7
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
RGCC-mediated PLK1 activity drives breast cancer lung metastasis by phosphorylating AMPKalpha2 to activate oxidative phosphorylation and fatty acid oxidation.
Cheng S, Wan X, Yang L, Qin Y, Chen S, Liu Y, Sun Y, Qiu Y, Huang L, Qin Q, Cui X, Wu M, Liu M. Cheng S, et al. J Exp Clin Cancer Res. 2023 Dec 15;42(1):342. doi: 10.1186/s13046-023-02928-2. J Exp Clin Cancer Res. 2023. PMID: 38102722 Free PMC article.
BACKGROUND: More than 90% of the mortality of triple-negative breast cancer (TNBC) patients is attributed to cancer metastasis with organotropism. ...RGCC activates AMPKalpha2 and downstream signaling through RGCC-driven PLK1 activity to facilitate TNB …
BACKGROUND: More than 90% of the mortality of triple-negative breast cancer (TNBC) patients is attributed to cancer metastasis …
Adoptive Cellular Transfer Immunotherapies for Cancer.
Parsonidis P, Papasotiriou I. Parsonidis P, et al. Cancer Treat Res Commun. 2022;32:100575. doi: 10.1016/j.ctarc.2022.100575. Epub 2022 May 13. Cancer Treat Res Commun. 2022. PMID: 35679756 Free article. Review.
Patients with cancer require efficient treatment approaches as the mortality rate due to their disease is high. ...The concept involves the isolation of immune cells, ex vivo activation and reinfusion into the patient. The goal is to boost the immune cells to fight canc …
Patients with cancer require efficient treatment approaches as the mortality rate due to their disease is high. ...The concept involv …
Role of C5b-9 and RGC-32 in Cancer.
Vlaicu SI, Tatomir A, Rus V, Rus H. Vlaicu SI, et al. Front Immunol. 2019 May 9;10:1054. doi: 10.3389/fimmu.2019.01054. eCollection 2019. Front Immunol. 2019. PMID: 31156630 Free PMC article. Review.
., Gi protein/ phosphatidylinositol 3-kinase (PI3K)/Akt kinase and Ras/Raf1/ERK1) and modulating the activation of cancer-related transcription factors, while shielding malignant cells from apoptosis. ...In this review, we present recent data describing the versatile, mult …
., Gi protein/ phosphatidylinositol 3-kinase (PI3K)/Akt kinase and Ras/Raf1/ERK1) and modulating the activation of cancer-related tra …
Nonylphenol Promoted Epithelial-Mesenchymal Transition in Colorectal Cancer Cells by Upregulating the Expression of Regulator of Cell Cycle.
Zhang NJ, Zhang Y, Yin S, Ruan DJ, He N, Chen X, Yang XF. Zhang NJ, et al. Chem Res Toxicol. 2022 Sep 19;35(9):1533-1540. doi: 10.1021/acs.chemrestox.2c00180. Epub 2022 Sep 8. Chem Res Toxicol. 2022. PMID: 36074022 Free PMC article.
Nonylphenol (NP) is a widely used chemical, which has been considered a kind of endocrine-disrupting chemical and is involved in the occurrence and development of many types of cancers. Our recent studies demonstrated that NP exposure is related to colorectal cancer …
Nonylphenol (NP) is a widely used chemical, which has been considered a kind of endocrine-disrupting chemical and is involved in the occurre …
Current perspectives on CHEK2 mutations in breast cancer.
Apostolou P, Papasotiriou I. Apostolou P, et al. Breast Cancer (Dove Med Press). 2017 May 12;9:331-335. doi: 10.2147/BCTT.S111394. eCollection 2017. Breast Cancer (Dove Med Press). 2017. PMID: 28553140 Free PMC article. Review.
Loss of kinase function has been correlated with different types of cancer, mainly breast cancer. CHEK2 functionality is affected by different missense or deleterious mutations. ...The present article reviews the recent advances in research on CHEK2 mutations, focus …
Loss of kinase function has been correlated with different types of cancer, mainly breast cancer. CHEK2 functionality is affec …
Increased breast cancer cell sensitivity to cisplatin using a novel small molecule inhibitor.
Hatzidaki E, Daikopoulou V, Apostolou P, Ntanovasilis DA, Papasotiriou I. Hatzidaki E, et al. J Cancer Res Ther. 2020 Oct-Dec;16(6):1393-1401. doi: 10.4103/jcrt.JCRT_677_19. J Cancer Res Ther. 2020. PMID: 33342803 Free article.
BACKGROUND: Although cisplatin is used for the treatment of more than half of cancer patients, its use is restricted by serious side effects as well as the development of cisplatin-resistant cancer cells, limiting its use. ...AIMS AND OBJECTIVES: The aim of the stud …
BACKGROUND: Although cisplatin is used for the treatment of more than half of cancer patients, its use is restricted by serious side …
Predicting prognosis through the discovery of specific biomarkers according to colorectal cancer lymph node metastasis.
Park SW, Kang J, Kim HS, Yoon S, Kim BS, Lim C, Lee D, Kim YH. Park SW, et al. Am J Cancer Res. 2023 Jul 15;13(7):3221-3233. eCollection 2023. Am J Cancer Res. 2023. PMID: 37559990 Free PMC article.
Colorectal cancer (CRC) is a prevalent cancer worldwide, ranking as the third most common cancer and the second leading cause of cancer-related deaths. ...The combination of differentially expressed genes and their involvement in cancer-related …
Colorectal cancer (CRC) is a prevalent cancer worldwide, ranking as the third most common cancer and the second leading …
RGC-32 and diseases: the first 20 years.
Vlaicu SI, Tatomir A, Anselmo F, Boodhoo D, Chira R, Rus V, Rus H. Vlaicu SI, et al. Immunol Res. 2019 Jun;67(2-3):267-279. doi: 10.1007/s12026-019-09080-0. Immunol Res. 2019. PMID: 31250246 Review.
Accumulating evidence has drawn attention to the deregulated expression of RGC-32 in human cancers, atherogenesis, metabolic disorders, and autoimmune disease. ...
Accumulating evidence has drawn attention to the deregulated expression of RGC-32 in human cancers, atherogenesis, metabolic disorder …
CTLs, NK cells and NK-derived EVs against breast cancer.
Parsonidis P, Mamagkaki A, Papasotiriou I. Parsonidis P, et al. Hum Immunol. 2023 May-Jul;84(5-7):320-326. doi: 10.1016/j.humimm.2023.03.001. Epub 2023 Mar 14. Hum Immunol. 2023. PMID: 36925436
Patients with advanced stage breast cancer need novel therapies. New potential treatments have been developed, such as adoptive cellular therapies and alternative cell-free immunotherapies. The goal of this study was to assess the cytotoxicity of three of the patient-deriv …
Patients with advanced stage breast cancer need novel therapies. New potential treatments have been developed, such as adoptive cellu …
Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.
Vlaicu SI, Tegla CA, Cudrici CD, Danoff J, Madani H, Sugarman A, Niculescu F, Mircea PA, Rus V, Rus H. Vlaicu SI, et al. Immunol Res. 2013 May;56(1):109-21. doi: 10.1007/s12026-012-8381-8. Immunol Res. 2013. PMID: 23247987 Review.
However, sublytic C5b-9 induces cell cycle progression by activating signal transduction pathways and transcription factors in cancer cells, indicating a role in tumor promotion for this complement complex. ...RGC-32 is expressed by tumor cells and plays a dual role in …
However, sublytic C5b-9 induces cell cycle progression by activating signal transduction pathways and transcription factors in cancer …
63 results